当前位置: 首页 >> 检索结果
25. Prevalence and Burden of Cardiac Amyloidosis in a Population-Based Autopsy Cohort.
作者: Andrew J Layman.;Martha Grogan.;Christopher G Scott.;Celine M Vachon.;Angela Dispenzieri.;Morie A Gertz.;Omar F AbouEzzeddine.;Melanie C Bois.;Ying-Chun Lo.;Marie-Christine Aubry.;Surendra Dasari.;Julie A Vrana.;Jason D Theis.;Ellen D McPhail.;Joseph J Maleszewski.
来源: Circulation. 2026年153卷23期1874-1876页 26. Activation of HIF2 in Cardiac Vasculature Leads to Arterial Remodeling, Dilation, Thrombosis, and Inflammation, Recapitulating Cardiac Involvement in Kawasaki Disease.
作者: B Escobar.;I Menendez-Montes.;T Albendea-Gomez.;S Mendoza-Tamajon.;R Castro-Mecinas.;S Urra-Balduz.;B Palacios.;M J Gómez.;C Diaz-Diaz.;F Sánchez-Cabo.;J Ruiz-Cabello.;L J Jimenez-Borreguero.;M C Cid.;K Takahashi.;S Martin-Puig.
来源: Circulation. 2026年
Global Vhl knockout results in vascular defects and early lethality, limiting our knowledge of von Hippel-Lindau/HIF (hypoxia-inducible factor) signaling in coronary vessel formation and homeostasis. The hypoxia pathway has been implicated in cardiovascular diseases characterized by inflammation and vascular remodeling, such as atherosclerosis, but its involvement in Kawasaki disease (KD) remains unknown. Coronary artery dilation and vessel rupture are the most serious complications of KD. However, the molecular mechanisms underlying these cardiac events are not fully understood. We investigated the role of the von Hippel-Lindau/HIF pathway in cardiovascular pathology and its relevance to KD.
27. Performance of Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease in the All of Us Program.
作者: Johanna L Smith.;Kristjan Norland.;Marwan E Hamed.;Yue Yu.;Jie Na.;Ozan Dikilitas.;Daniel J Schaid.;Iftikhar J Kullo.
来源: Circ Genom Precis Med. 2026年e005382页
Performance and transferability of contemporary polygenic risk scores (PRS) for atherosclerotic cardiovascular disease phenotypes may vary across PRS methods, training data, and trait ascertainment.
30. Aberrant Phase Separation of Endothelial MAML1 Causes Congenital Heart Disease by Suppressing Notch Activity.
作者: Zizheng Tan.;Yue Qi.;Yujia Chen.;Liang Zhang.;Chao Li.;Bingkun Lei.;Ziqi Xiao.;Jingyan Zhang.;Lei Lu.;Hongyan Wang.
来源: Circulation. 2026年
Congenital heart disease (CHD), the most common birth defect and a leading cause of infant mortality, is frequently linked to dysregulated Notch signaling. However, the role of the Notch transcriptional coactivator Mastermind-like 1 (MAML1) in CHD pathogenesis and the underlying molecular mechanism remain unclear.
31. Epicardial Contributions to Fibro-Inflammatory Signaling in a Pkp2-Deficient Arrhythmogenic Cardiomyopathy Model.
作者: Daniel D Han.;Alan C Brooks.;Cameron D Baker.;Ronald A Dirkx.;Deanne M Mickelsen.;Benjamin Fisler.;Kavya Phadke.;John M Ashton.;Mario Delmar.;Eric M Small.
来源: Circ Heart Fail. 2026年e013966页
Arrhythmogenic cardiomyopathy (ACM) is an inherited disease that is characterized by lethal ventricular arrhythmias stemming from myocyte dysfunction. ACM is associated with considerable subepicardial fibrosis and inflammation with right ventricle predominance. Most cases of gene-positive ACM are caused by a desmosome protein mutation, with plakophilin-2 (Pkp2) mutations being the most common. We hypothesized that Pkp2-deficiency in epicardium-derived cells (EPDCs) contributes to fibro-inflammatory signaling and ACM pathogenesis.
32. Machine Learning Reveals the Contribution of Rare Genetic Variants and Enhances Risk Prediction for Coronary Artery Disease in the Japanese Population.
作者: Hirotaka Ieki.;Sai Zhang.;Satoshi Koyama.;Martin Kjellberg.;Hiroki Yoshida.;Ryo Kurosawa.;Hiroshi Matsunaga.;Kazuo Miyazawa.;Nobuyuki Enzan.;Changhoon Kim.;Jeong-Sun Seo.;Koichiro Higasa.;Kouichi Ozaki.;Yoshihiro Onouchi.;Koichi Matsuda.;Yoichiro Kamatani.;Chikashi Terao.;Fumihiko Matsuda.;Michael Snyder.;Issei Komuro.;Kaoru Ito.; .
来源: Circ Genom Precis Med. 2026年e005341页
GWASs (genome-wide association studies) have advanced our understanding of coronary artery disease (CAD) genetics and enabled the development of polygenic risk scores (PRSs) for estimating genetic risk based on common variant burden. However, GWASs have limitations in analyzing rare variants due to insufficient statistical power, thereby constraining PRS performance.
33. Incremental Prognostic Value of Subendocardial Myocardial Flow Reserve in Patients With Normal Perfusion.
作者: Diana M Lopez.;Jenifer M Brown.;Sanjay Divakaran.;Daniel M Huck.;Brittany N Weber.;Jon Hainer.;Sylvain Carre.;Mark Lemley.;Giselle Ramirez.;Aakash Shanbhag.;Paul Kavanagh.;Joanna X Liang.;Ron Blankstein.;Sharmila Dorbala.;Damini Dey.;Stacey Knight.;Viet T Le.;Steve Mason.;Samuel Wopperer.;Panithaya Chareonthaitawee.;Thomas L Rosamond.;Jacek Kwiecinski.;Robert J H Miller.;Leandro Slipczuk.;Mark I Travin.;Erick Alexanderson.;Isabel Carvajal-Juarez.;René R S Packard.;Mouaz Al-Mallah.;Andrew J Einstein.;Attila Feher.;Wanda Acampa.;Rupa Sanghani.;Ronny R Buechel.;Robert A deKemp.;Daniel S Berman.;Piotr J Slomka.;Marcelo F Di Carli.
来源: Circulation. 2026年
Although the prognostic utility of positron emission tomography (PET) myocardial flow reserve (MFR) is well established, emerging data suggest that reduced subendocardial flows also predict adverse outcomes. However, the incremental value of subendocardial MFR (MFRSE) beyond transmural MFR (MFRTM) remains unclear.
34. Age and Procedural Timing for Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.
作者: Kashish Goel.;Brian R Lindman.;Allan Schwartz.;David J Cohen.;Gennaro Giustino.;J Bradley Oldemeyer.;Justin Strote.;Vasilis Babaliaros.;Chandan M Devireddy.;Michael P Fischbein.;William F Fearon.;David Daniels.;Christian Spies.;Adnan K Chhatriwalla.;Hussam S Suradi.;Pinak Shah.;Molly Szerlip.;Thom Dahle.;Dimitrios Apostolou.;Raj Makkar.;Charles J Davidson.;Tej Sheth.;Paul Sorajja.;James T DeVries.;Jeffrey Southard.;Jeremiah P Depta.;Andrei Pop.;Michael J Rinaldi.;Salem Badr.;Mathew R Williams.;Mark J Russo.;Mayra Guerrero.;James M McCabe.;Philippe Pibarot.;Yizhuo Wang.;Martin B Leon.;Philippe Généreux.
来源: Circ Cardiovasc Interv. 2026年e016370页
The EARLY TAVR trial demonstrated that early transcatheter aortic valve replacement (TAVR) was superior to clinical surveillance (CS) in asymptomatic severe aortic stenosis. The relative impact of early TAVR versus a CS strategy by age is unknown.
35. Impact of Revascularization Completeness on Cardiovascular Outcomes in STEMI With Multivessel Disease.
作者: Mehdi Madanchi.;Natalia Pinilla-Echeverri.;David A Wood.;Tej Sheth.;Robert F Storey.;Vijay Kunadian.;Gianluca Campo.;Raul Moreno.;Roxana Mehran.;Sunil V Rao.;Kevin R Bainey.;Tomas Cieza.;Helen Nguyen.;Thenmozhi Mani.;John A Cairns.;Shamir R Mehta.
来源: Circ Cardiovasc Interv. 2026年e016515页
Complete revascularization is superior to culprit lesion-only percutaneous coronary intervention (PCI) in reducing ischemic events in patients with ST-segment-elevation myocardial infarction and multivessel disease. However, the relationship between the extent of revascularization and the benefits of a complete revascularization strategy remains unclear. The aim of this substudy of the COMPLETE trial was to evaluate how the degree of anatomic completeness of revascularization, measured by the core laboratory-derived modified residual SYNTAX score (R'SS), relates to major cardiovascular events.
36. Lifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Assessed 5- and 10-Year Follow-Up After 2 Clinical Trials.
作者: Hadar Klein.;Liav Alufer.;Dana Tamar Goldberg Toren.;Dafna Pachter.;Omer Kamer.;Noa Ebstein Karamani.;Yoash Chassidim.;Ilan Shelef.;Assaf Rudich.;Uri Yoel.;Gal Ben-Arie.;Hila Zelicha.;Anat Yaskolka Meir.;Gal Tsaban.;Carmi Bartal.;Matthias Blüher.;Michael Stumvoll.;Uta Ceglarek.;Berend Isermann.;Lu Qi.;Meir J Stampfer.;Frank B Hu.;Iris Shai.
来源: Circulation. 2026年
During the 18-month CENTRAL (Effect of Weight-Loss Diet Strategies and Exercise on Dynamics of Body Fat Depots and Metabolic Rate) and DIRECT-PLUS (Effects of Green-Mediterranean Diet via the Gut-Fat-Brain Axis) randomized controlled trials, participants achieved considerable reductions in abdominal and ectopic fat. We examined the long-term postintervention cardiometabolic profile associated with these changes.
37. Cardiomyopathy and Sudden Cardiac Death as a Rare Presentation of Mucolipidosis Type III in a Family With Compound Heterozygous Variants in GNPTAB.
作者: Natalie Stewart.;Natasha Henden.;Carlos C Smith-Díaz.;Jennifer Rigby.;Alexandra Butters.;Amy Baker.;Laura Catto.;Inuli Subasinghe.;Laura Yeates.;Lucy Geraghty.;Jasmine Follett.;David Sillence.;Leah Kemp.;Ira W Deveson.;Muayad Alasady.;Sharon Wilson.;Cas Simons.;Daniel G MacArthur.;Belinda Gray.;Johan Duflou.;Mary-Louise Freckmann.;Ebony Richardson.;Andreas Zankl.;Jodie Ingles.
来源: Circ Genom Precis Med. 2026年e005703页 38. Performance of Local Large Language Models for Adjudicating Heart Failure Hospitalizations.
作者: Rahul Aggarwal.;Andrew S Oseran.;Arjun K Manrai.;Lucas X Marinacci.;Deepak L Bhatt.;Robert W Yeh.;Jennifer E Ho.;Adam Rodman.;Rishi K Wadhera.
来源: Circulation. 2026年153卷22期1785-1787页 40. Letter by Jiang et al Regarding Article, "Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial". |